Logo

Proteome Systems Licenses Ovarian Cancer Protein from Westmead Millennium Institute

Oct 20, 2004

NEW YORK, Oct. 20 (GenomeWeb News) - Proteome Systems of Australia has licensed a potential biomarker for ovarian cancer from the Children's Hospital at Westmead and Westmead Millennium Institute of Sydney, the company said today.

 

Proteome Systems plans to evaluate the protein biomarker for inclusion in a non-invasive test for the early detection of ovarian cancer the company has been developing.

 

The company said it is currently evaluating two other proteins identified from plasma samples using its proteomics technology

Breaking News
The Scan

Vaccine Update Recommended

A US Food and Drug Administration panel recommends booster vaccines be updated to target Omicron, CNBC reports.

US to Make More Vaccines for Monkeypox Available

The US is to make nearly 300,000 vaccine doses available in the coming weeks to stem the spread of human monkeypox virus, according to NPR.

Sentence Appealed

The Associated Press reports that Swedish prosecutors are appealing the sentence given to a surgeon once lauded for transplanting synthetic tracheas but then convicted of causing bodily harm.

Genome Biology Papers on COVID-19 Effector Genes, Virtual ChIP-seq, scDART

In Genome Biology this week: proposed COVID-19 effector genes, method to predict transcription factor binding patterns, and more.